Segment information (Tables)

9 Months Ended

Sep. 30, 2026

Segment information

Schedule of segment financial information

The table below is a summary of the segment net loss, including significant segment expense categories (in thousands):

	Three Months Ended September 30,						Nine Months Ended September 30,
	2026			2025			2026			2025
Collaboration revenue	$	—		$	—		$	—		$	6,941
Less:
Direct research and development expenses(1)
Varegacestat		12,579			12,495			33,128			39,615
IM-1021		9,578			2,874			19,789			7,669
IM-1617		1,629			5,465			4,496			9,397
IM-1340		1,725			3,322			7,261			4,811
IM-3050		2,229			2,104			5,092			4,149
Other direct research and development		13,265			6,404			31,565			15,081
Indirect research and development(2)		21,062			13,143			57,768			36,593
General and administrative(3)		14,530			6,997			36,652			21,246
Other segment expenses(4)		13,765			7,334			32,077			19,632
Total operating expenses		90,362			60,138			227,828			158,193
Loss from operations		(90,362	)		(60,138	)		(227,828	)		(151,252	)
Interest income		4,579			2,681			15,079			8,758
Net loss		(85,783	)	$	(57,457	)	$	(212,749	)	$	(142,494	)